Jamadagni, S., Pandkar, P., Saundankar, T., Shirke, G., Malekar, S., & Vaidya, V. (2022). Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial. Elsevier.
Chicago Style (17th ed.) CitationJamadagni, Sameer, Prasad Pandkar, Tushar Saundankar, Girish Shirke, Shailesh Malekar, and V.G Vaidya. Efficacy of Madhav Rasayan Plus as Adjuvant in Moderate COVID-19 Patients: Preliminary Outcomes of Randomized Controlled Trial. Elsevier, 2022.
ציטוט MLAJamadagni, Sameer, et al. Efficacy of Madhav Rasayan Plus as Adjuvant in Moderate COVID-19 Patients: Preliminary Outcomes of Randomized Controlled Trial. Elsevier, 2022.
אזהרה: ציטוטים אלה לעיתים לא מדויקים ב 100%.